(HealthDay)—Xeljanz (tofacitinib) has been approved by the U.S. Food and Drug Administration to treat symptoms of rheumatoid arthritis (RA) among people who can't tolerate, or haven't been helped by, the drug methotrexate.
Arthritis & Rheumatism Nov 07, 2012 | not rated yet | 0
(AP)—Drug giant Pfizer Inc. said Thursday that its third-quarter profit fell 14 percent as sales plunged, mainly due to U.S. generic competition to cholesterol fighter Lipitor, long the world's top-selling drug.
Other Nov 01, 2012 | not rated yet | 0
(AP)—Pfizer said Monday it will buy NextWave Pharmaceuticals Inc., a company that makes a liquid attention deficit hyperactivity disorder drug, in a deal worth as much as $700 million.
Medications Oct 22, 2012 | not rated yet | 0
A simple, five-question patient-administered survey (COPD-PS) may lead to increased diagnoses of chronic obstructive pulmonary disease (COPD).
Diseases, Conditions, Syndromes Oct 22, 2012 | not rated yet | 0
(AP)—Advisers to European Union regulators have recommended approval of a new anti-clotting drug for use by adults with a common irregular heart rhythm that boosts risk of strokes or blood clots, drugmakers Bristol-Myers ...
Medications Sep 21, 2012 | 5 / 5 (1) | 0
An experimental drug that failed to stop mental decline in Alzheimer's patients in the U.S. and Canada also showed some potential benefit in slowing brain plaque, fuller results of two major studies show.
Alzheimer's disease & dementia Sep 11, 2012 | not rated yet | 0
Pfizer Inc. says the Food and Drug Administration on Tuesday approved its new drug to treat a rare form of blood and bone marrow cancer.
Medications Sep 04, 2012 | not rated yet | 0
Pfizer Inc. and Johnson & Johnson say they are ending development of a once-promising drug designed to treat Alzheimer's disease after the treatment failed in two late-stage clinical trials.
Alzheimer's disease & dementia Aug 06, 2012 | not rated yet | 0
Drugmaker Pfizer Inc.'s second-quarter net income jumped 25 percent as sharply lower costs for production, marketing and restructuring more than offset a plunge in revenue from cholesterol fighter Lipitor ...
Other Jul 31, 2012 | not rated yet | 0
(AP) A closely watched experimental Alzheimer's treatment has failed to slow the disease in one late-stage study, a big disappointment for doctors and patients but not the end of the road for the drug. Pfizer Inc. ...
Alzheimer's disease & dementia Jul 23, 2012 | not rated yet | 0
Scientists from The Scripps Research Institute and Pfizer Inc. have published a new study showing how a new drug called tafamidis (Vyndaqel) works. Tafamidis, approved for use in Europe and currently under ...
Medical research May 29, 2012 | 5 / 5 (3) | 0 |
A new study that tracked what Alzheimer's disease and related disorders (ADRD) costs Medicare during three distinct stages of patient care suggests that the government insurer could realize substantial savings ...
Health Apr 10, 2012 | not rated yet | 0
(HealthDay) -- Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic ...
Cancer Mar 29, 2012 | not rated yet | 0
Watching Alzheimer's disease steal away the memory, talents and very selves of its victims is hard enough for the people who love them. But a new pill formulated by a respected pharmaceutical company and approved by the Food ...
Alzheimer's disease & dementia Mar 23, 2012 | 5 / 5 (1) | 0
(HealthDay) -- A U.S. Food and Drug Administration advisory panel on Monday will weigh the wisdom of allowing new clinical trials of a class of powerful painkillers for osteoarthritis. The drugs may have worked ...
Medications Mar 12, 2012 | not rated yet | 0